{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:12:24Z","timestamp":1758478344183,"version":"3.30.0"},"reference-count":45,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14799","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T12:22:43Z","timestamp":1731414163000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the efficacy of PD\u20111\/PD\u2011L1 inhibitor plus bevacizumab and chemotherapy for the treatment of patients with driver gene\u2011negative advanced\u2011stage lung adenocarcinoma: A retrospective cohort study"],"prefix":"10.3892","volume":"29","author":[{"given":"Xiaozun","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Jianzhu Hospital, Chengdu, Sichuan 610000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"key20241202101952_b1-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20241202101952_b2-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/fon-2022-1214","article-title":"2022 cancer statistics: Focus on lung cancer","volume":"5","author":"Jenkins","year":"2023","journal-title":"Future Oncol"},{"key":"key20241202101952_b3-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"17588359231163798","DOI":"10.1177\/17588359231163798","article-title":"Neoadjuvant immunotherapy in resectable non-small-cell lung cancer","volume":"15","author":"Chen","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"key20241202101952_b4-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3390\/cancers14071759","article-title":"Lung adenocarcinoma tumor origin: A guide for personalized medicine","volume":"14","author":"Seguin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20241202101952_b5-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3390\/curroncol29030150","article-title":"Non-small-cell lung cancer in 2022: A review for general practitioners in oncology","volume":"29","author":"Mithoowani","year":"2022","journal-title":"Curr Oncol"},{"key":"key20241202101952_b6-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"key20241202101952_b7-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: State of the art and future directions","volume":"44","author":"Miao","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"key20241202101952_b8-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11684-022-0976-4","article-title":"Treatment of advanced non-small cell lung cancer with driver mutations: Current applications and future directions","volume":"17","author":"Zhong","year":"2023","journal-title":"Front Med"},{"key":"key20241202101952_b9-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"key20241202101952_b10-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"key20241202101952_b11-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20241202101952_b12-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s11033-022-07982-1","article-title":"Analyses of P16(INK4a) gene promoter methylation relative to molecular, demographic and clinical parameters characteristics in non-small cell lung cancer patients: A pilot study","volume":"50","author":"Jurisic","year":"2023","journal-title":"Mol Biol Rep"},{"key":"key20241202101952_b13-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.1007\/s13277-016-4930-4","article-title":"Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: A preliminary study","volume":"37","author":"Obradovic","year":"2016","journal-title":"Tumour Biol"},{"key":"key20241202101952_b14-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41588-019-0569-6","article-title":"Genomic landscape of lung adenocarcinoma in East Asians","volume":"52","author":"Chen","year":"2020","journal-title":"Nat Genet"},{"key":"key20241202101952_b15-ol-29-1-14799","first-page":"205","article-title":"Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations","volume":"3","author":"Mitsudomi","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"key20241202101952_b16-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/ol.2022.13649","article-title":"Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis","volume":"25","author":"Obradovic","year":"2023","journal-title":"Oncol Lett"},{"key":"key20241202101952_b17-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1973241","DOI":"10.1155\/2020\/1973241","article-title":"EGFR polymorphism and survival of NSCLC patients treated with TKIs: A systematic review and meta-analysis","volume":"2020","author":"Jurisic","year":"2020","journal-title":"J Oncol"},{"key":"key20241202101952_b18-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20241202101952_b19-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"key20241202101952_b20-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line Carboplatin\/Paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20241202101952_b21-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"816","DOI":"10.20892\/j.issn.2095-3941.2020.0212","article-title":"Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: A phase 3 randomized, double-blind clinical trial","volume":"18","author":"Chu","year":"2021","journal-title":"Cancer Biol Med"},{"key":"key20241202101952_b22-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"key20241202101952_b23-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"16025","DOI":"10.1038\/cddiscovery.2016.25","article-title":"Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients","volume":"2","author":"Martino","year":"2016","journal-title":"Cell Death Discov"},{"key":"key20241202101952_b24-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/sj.bjc.6604965","article-title":"Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes","volume":"100","author":"Alfaro","year":"2009","journal-title":"Br J Cancer"},{"key":"key20241202101952_b25-ol-29-1-14799","first-page":"881","article-title":"The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions","volume":"29","author":"Wada","year":"2009","journal-title":"Anticancer Res"},{"key":"key20241202101952_b26-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"17588359211029826","DOI":"10.1177\/17588359211029826","article-title":"Research progress in immune checkpoint inhibitors for lung cancer in China","volume":"13","author":"Gan","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"key20241202101952_b27-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20241202101952_b28-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2147\/JHC.S284440","article-title":"PD-1 blockade for hepatocellular carcinoma: Current research and future prospects","volume":"8","author":"D'Alessio","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"key20241202101952_b29-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"key20241202101952_b30-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"key":"key20241202101952_b31-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"author":"U.S. Department Of","key":"key20241202101952_b32-ol-29-1-14799","article-title":"National Institutes of Health and National Cancer Institute: Common terminology criteria for adverse events (CTCAE) version 4.02"},{"key":"key20241202101952_b33-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"key20241202101952_b34-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"article-title":"NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer","year":"2018","author":"Network","key":"key20241202101952_b35-ol-29-1-14799"},{"key":"key20241202101952_b36-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: Management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"key20241202101952_b37-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"key20241202101952_b38-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key20241202101952_b39-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"key20241202101952_b40-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"key20241202101952_b41-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1093\/annonc\/mdw416","article-title":"Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: A four arms phase Ib study","volume":"27","author":"Kanda","year":"2016","journal-title":"Ann Oncol"},{"key":"key20241202101952_b42-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1111\/cas.14410","article-title":"Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer","volume":"111","author":"Kanda","year":"2020","journal-title":"Cancer Sci"},{"key":"key20241202101952_b43-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"101799","DOI":"10.1016\/j.tranon.2023.101799","article-title":"Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients","volume":"38","author":"Martinovic","year":"2023","journal-title":"Transl Oncol"},{"key":"key20241202101952_b44-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"e14566","DOI":"10.7717\/peerj.14566","article-title":"Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors","volume":"10","author":"Chen","year":"2022","journal-title":"PeerJ"},{"key":"key20241202101952_b45-ol-29-1-14799","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-94-017-7215-0_8","article-title":"The actual role of LDH as tumor marker, biochemical and clinical aspects","volume":"867","author":"Jurisic","year":"2015","journal-title":"Adv Exp Med Biol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:20:00Z","timestamp":1733127600000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14799","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"article-number":"53"}}